FDA Using “Dual-Track” Plan To Strengthen 2005-2006 Flu Vaccine Supply
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will inspect Chiron’s Liverpool manufacturing facility in the spring to determine whether the company has “adequately addressed its problems,” CBER Director Goodman tells House committee. FDA informs manufacturers that it will allow accelerated approval of flu vaccines using surrogate endpoints.